DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	4.54	4.73	4.71	7.42	3.97
Short-Term Investments	48.35	28.77	40.41	20.1	4
Cash & Cash Equivalents	52.9	33.5	45.11	27.52	7.97
Cash Growth	57.89%	-25.74%	63.94%	245.43%	-52.65%
Receivables	0.37	0.08	0.13	0.34	0.82
Other Current Assets	0.41	0.25	0.2	0.06	0.05
Total Current Assets	53.68	33.84	45.44	27.92	8.84
Property, Plant & Equipment	0.49	0.56	0.11	0.17	0.22
Total Long-Term Assets	0.49	0.56	0.11	0.17	0.22
Total Assets	54.16	34.4	45.55	28.1	9.05
Accounts Payable	0.93	0.73	0.51	1.1	0.18
Current Debt	0.08	0.07	0.05	0.07	0.06
Other Current Liabilities	1.78	1.37	0.97	0.86	1.08
Total Current Liabilities	2.79	2.17	1.52	2.03	1.32
Long-Term Debt	0.32	0.4	0	0.05	0.12
Total Long-Term Liabilities	0.32	0.4	0	0.05	0.12
Total Liabilities	3.1	2.57	1.53	2.08	1.44
Total Debt	0.4	0.47	0.05	0.12	0.18
Debt Growth	-14.71%	801.92%	-55.93%	-33.71%	673.91%
Retained Earnings	-115.56	-96.18	-82.5	-68.91	-56.62
Comprehensive Income	0.01	-0.07	-0.05	-0	0
Shareholders' Equity	51.06	31.83	44.02	26.01	7.62
Net Cash / Debt	52.5	33.03	45.06	27.4	7.79
Net Cash / Debt Growth	58.92%	-26.69%	64.46%	251.81%	-53.64%
Net Cash Per Share	1.61	1.25	2.17	1.75	0.65
Working Capital	50.89	31.67	43.92	25.89	7.52
Book Value Per Share	1.57	1.20	2.12	1.66	0.64

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).